{
  "nctId": "NCT04842929",
  "briefTitle": "Magnetic Randomized Trial in Elderly Depressed",
  "officialTitle": "Treatment of Depression in the Elderly With Repetitive Transcranial Magnetic Stimulation (rTMS) Using Theta-burst Stimulation (TBS): Randomized, Double-blind, Sham-controlled, Clinical Trial",
  "protocolDocument": {
    "nctId": "NCT04842929",
    "filename": "Prot_SAP_002.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2021-10-29",
    "uploadDate": "2021-10-29T07:11",
    "size": 273941,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04842929/document/Prot_SAP_002.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "QUADRUPLE",
  "enrollmentInfo": {
    "enrollmentCount": 108,
    "enrollmentType": "ESTIMATED"
  },
  "timeline": {
    "startDate": "2019-01-16",
    "completionDate": "2022-12-20",
    "primaryCompletionDate": "2022-09-20",
    "firstSubmitDate": "2021-01-20",
    "firstPostDate": "2021-04-13"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Major Depressive Disorder;\n* Patients older than 60 years\n* Hamilton equal or higher than 17\n\nExclusion Criteria:\n\n* Other mental disorders (alcohol or drug addiction, psychotic disorders, dementia, bipolar disorder);\n* Presence of serious neurological or clinical diseases;\n* Resence of severe suicidal ideation and CIRS (Cumulative Illness Rating Scale) score\\> 7, characterizing a set of clinical morbidities that could impair adherence to the research protocol, bipolar disorder and/or presence of manic symptoms (hypo) demonstrated with more than 8 points in the Young Mania Rating Scale.\n* Metal implants;\n* Epilepsy or electronics in the cephalic segment;",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "60 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Changes in Hamilton Rating Scale for Depression, 17 items (HDRS-17)",
        "description": "Continuous measure (score changes).",
        "timeFrame": "Weeks 0 and 6"
      }
    ],
    "secondary": [
      {
        "measure": "Change in HDRS-17",
        "description": "Continuous measure (score changes).",
        "timeFrame": "Weeks 1, 2, 4, 6, 8, 12"
      },
      {
        "measure": "Change in Montgomery-Asberg Depression Rating Scale (MADRS)",
        "description": "Continuous measure (score changes).",
        "timeFrame": "Weeks 1, 2, 4, 6, 8, 12"
      },
      {
        "measure": "Change in Global Clinical Impression Scale (CGI)",
        "description": "Continuous measure (score changes).",
        "timeFrame": "Weeks 1, 2, 4, 6, 8, 12"
      },
      {
        "measure": "Change in Cumulative Illness Rating Scale (CIRS)",
        "description": "Continuous measure (score changes).",
        "timeFrame": "Weeks 1, 2, 4, 6, 8, 12"
      },
      {
        "measure": "Change in Geriatric Depression Scale (GDS)",
        "description": "Continuous measure (score changes).",
        "timeFrame": "Weeks 1, 2, 4, 6, 8, 12"
      },
      {
        "measure": "Change in Positive and Negative Affect Scale (PANAS)",
        "description": "Continuous measure (score changes).",
        "timeFrame": "Weeks 1, 2, 4, 6, 8, 12"
      },
      {
        "measure": "Change in serum BDNF concentrations",
        "description": "Continuous measure (score changes).",
        "timeFrame": "Weeks 0 and 6"
      },
      {
        "measure": "Response HDRS 17",
        "description": "Response (≥50% improvement from week 0 to 12)",
        "timeFrame": "Week 12"
      },
      {
        "measure": "Remission of HDRS 17",
        "description": "Remission (HDRS-17 ≤ 8)",
        "timeFrame": "Week 12"
      },
      {
        "measure": "Young Manic Rating Scale (YMRS)",
        "description": "Serious adverse events include treatment-emergent hypomania/mania (YMRS\\>8), suicide, psychiatric hospitalization and others life-threatening or incapacitant events",
        "timeFrame": "Weeks 0, 1, 2, 4, 6, 8, 12"
      },
      {
        "measure": "Serious adverse events",
        "description": "Serious adverse events include treatment-emergent hypomania/mania (YMRS\\>8), suicide, psychiatric hospitalization and others life-threatening or incapacitant events",
        "timeFrame": "Up to week 12"
      }
    ],
    "other": [
      {
        "measure": "Conditioned pain modulation",
        "description": "Temperature of the thermode reported as painful",
        "timeFrame": "Week 0 and 4"
      },
      {
        "measure": "Actigraphy",
        "description": "Continuous measure (score changes).",
        "timeFrame": "1 week before treatment up to 4 weeks after finishing study"
      }
    ]
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 11,
      "otherCount": 2,
      "totalCount": 14
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 98,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:29:18.313Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}